Further evidence about the crucial role of CSF biomarkers in diagnosis of posterior cortical atrophy

E. Coppi, L. Ferrari, R. Santangelo, F. Caso, P. Pinto, G. Passerini, G. Comi, G. Magnani

Research output: Contribution to journalArticle

Abstract

Cerebrospinal fluid (CSF) biomarkers (protein tau, phosphorylated tau and amyloid Beta 1-42) are recognized as a supportive feature in diagnosis of Alzheimer's disease (AD) and their role in identifying atypical variants of AD is currently under investigation. We dosed these proteins in nine patients clinically and instrumentally affected by posterior cortical atrophy (PCA), a rare disorder characterized by a progressive neurodegenerative process that involves primarily the posterior brain regions. We compared the obtained values with a large group of AD patients (N = 117), recruited in our neurological department. Our data revealed no differences in the CSF profile between PCA and AD, showing abnormal values of protein tau, phosphorylated tau and amyloid Beta 1-42 in both groups of patients. This study underlines the diagnostic importance of CSF biomarkers in PCA patients, supporting the hypothesis that PCA is an atypical variant of AD with an onset before the age of 65.

Original languageEnglish
Pages (from-to)785-787
Number of pages3
JournalNeurological Sciences
Volume35
Issue number5
DOIs
Publication statusPublished - 2014

Keywords

  • CSF biomarkers
  • Early-onset Alzheimer disease
  • Posterior cortical atrophy
  • Visuo-spatial impairment

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Further evidence about the crucial role of CSF biomarkers in diagnosis of posterior cortical atrophy'. Together they form a unique fingerprint.

  • Cite this